Review
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2025; 17(8): 109613
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.109613
Progress of immune checkpoint inhibitors in gastric cancer
Ji-Yun Wan, Duo Zhang, Xiang-Hua Wu, Hao Yang, Chao Dong
Ji-Yun Wan, Duo Zhang, Hao Yang, Department of Gastrointestinal Surgery, The Affiliated Tai’an City Central Hospital of Qingdao University, Tai’an 271000, Shandong Province, China
Ji-Yun Wan, Xiang-Hua Wu, Department of Gastrointestinal Gland Surgery, Guangxi Key Laboratory of Enhanced Recovery After Surgery for Gastrointestinal Cancer, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Chao Dong, Department of Hemodialysis, The Affiliated Tai’an City Central Hospital of Qingdao University, Tai’an 271000, Shandong Province, China
Author contributions: Wan JY was responsible for conceptualization, methodology, software, investigation, formal analysis, and writing original draft; Zhang D was responsible for visualization and investigation; Wu XH was responsible for resources, supervision, software, validation, visualization, writing review and editing; Yang H was responsible for methodology, software, visualization, and investigation; Dong C was responsible for conceptualization, funding acquisition, resources, supervision, writing review and editing; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chao Dong, Research Fellow, MRCP, Department of Hemodialysis, The Affiliated Tai’an City Central Hospital of Qingdao University, No. 29 Long Tan Road, Tai’an 271000, Shandong Province, China. dongchao689@163.com
Received: May 19, 2025
Revised: June 10, 2025
Accepted: July 4, 2025
Published online: August 15, 2025
Processing time: 89 Days and 21.4 Hours
Core Tip

Core Tip: Gastric cancer (GC) is a serious threat to human health. Immunotherapy is one of the important ways of clinical treatment of GC. Among them, immune checkpoint inhibitors (ICIs) have been applied in clinical practice, and the research on the combination therapy of ICIs has shown good therapeutic effect and lower treatment toxicity. This minireview summarizes the progress of immune ICIs in GC, discusses current individualized strategies, and explores future development directions.